- Home
- SPPL vs VYNE Comparison
SPPL vs VYNE Comparison
Compare SPPL & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPPL | VYNE |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 20.0M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SPPL | VYNE |
|---|---|---|
| Price | $2.18 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.0K | ★ 222.2K |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.29 |
| 52 Week High | $7.00 | $1.98 |
Technical Indicators
Market Signals| Indicator | SPPL | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 55.03 |
| Support Level | N/A | $0.56 |
| Resistance Level | $3.58 | $0.75 |
| Average True Range (ATR) | 0.29 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 21.90 | 63.05 |
Price Performance
Historical ComparisonAbout SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.